Human Gene Therapy - April 2023 - 258

258
GENE THERAPY BRIEFS
agency's active engagement as we
seek to deliver this important therapy
to patients with severe hemophilia
A,'' said Hank Fuchs, MD,
BioMarin's president of worldwide
research and development. ''The
three-year data enhance our application
and further reinforce our
belief that ROCTAVIAN has the
potential to fundamentally transform
care for people with hemophilia
A.''8
REFERENCES
1. Philippidis A. PASTE, Don't Cut: Genome Editing
Tool Looks Beyond CRISPR and Prime. Genetic
Engineering & Biotechnology News; March 10,
2023. Available from: https://www.geneng
news.com/topics/genome-editing/paste-dont-cutgenome-editing-tool-looks-beyond-crispr-and-prime/
[Last
accessed: March 15, 2023].
2. AbbVie and Capsida Biotherapeutics. AbbVie and
Capsida Biotherapeutics Expand Strategic Collaboration
to Develop Targeted Genetic Medicines
for Eye Diseases with High Unmet Need; February
23, 2023. Available from: https://news.abbvie
.com/news/press-releases/abbvie-and-capsida-bio
therapeutics-expand-strategic-collaboration-to-dev
elop-targeted-genetic-medicines-for-eye-diseaseswith-high-unmet-need.htm
[Last accessed: March
15, 2023].
3. Aera Therapeutics. Aera Therapeutics Launches
with $193 Million in Financing to Enable and
Advance the Next Generation of Transformative
Genetic Medicines; February 16, 2023. Available
from: https://aeratx.com/aera-therapeutics-laun
ches-with-193-million-in-financing-to-enable-andadvance-the-next-generation-of-transformativegenetic-medicines/
[Last accessed: March 15,
2023].
4. LeMieux J. Feng Zhang's Delivery Platform
Launched by Aera Therapeutics. Genetic Engineering
& Biotechnology News; February 16,
2023. Available from: https://www.genengnews
.com/topics/omics/gene-expression/gene-delivery/
feng-zhangs-delivery-platform-launched-by-aeratherapeutics/
[Last accessed: March 15, 2023].
5. Orchard Therapeutics. Orchard Therapeutics
Announces Strategic Financing Totalling up to
$188 Million; March 6, 2023. Available from:
https://ir.orchard-tx.com/news-releases/news-rele
ase-details/orchard-therapeutics-announces-strate
gic-financing-totalling-188 [Last accessed: March
15, 2023].
6. Philippidis A. Up or Down: Chroma Medicine
Raises Stakes in Epigenetic Editing. Genetic
Engineering & Biotechnology News; March 11,
2023. Available from: https://www.genengnews
.com/topics/genome-editing/up-or-down-chromamedicine-raises-stakes-in-epigenetic-editing/
[Last
accessed: March 15, 2023].
7. Chroma Medicine. Chroma Medicine Secures
$135M in Series B Financing to Advance Breakthrough
Epigenetic Editing Technology and
Expand Pipeline of Durable Precision Genomic
Medicines; March 1, 2023. Available from:
https://chromamedicine.com/2023/03/01/chromamedicine-secures-135m-in-series-b-financing-toadvance-breakthrough-epigenetic-editing-technol
ogy-and-expand-pipeline-of-durable-precision-gen
omic-medicines/
[Last accessed: March 15, 2023].
8. BioMarin Pharmaceutical. BioMarin Provides
Update on FDA Review of ROCTAVIAN
(Valoctocogene Roxaparvovec) Gene Therapy for
Adults with Severe Hemophilia A; March 6, 2023.
Available from: https://investors.biomarin.com/
2023-03-06-BioMarin-Provides-Update-on-FDA-Rev
iew-of-ROCTAVIAN-TM-Valoctocogene-Roxaparvo
vec-Gene-Therapy-for-Adults-with-Severe-Hemophi
lia-A [Last accessed: March 15, 2023].

Human Gene Therapy - April 2023

Table of Contents for the Digital Edition of Human Gene Therapy - April 2023